0      0

2021 AABB Annual Meeting On-Demand

AM21-56: COVID-19 Convalescent Plasma: Impact on Donation Safety and Eligibility


Oct 19, 2021 9:00pm ‐ Oct 19, 2021 10:00pm



Credits: None available.

Members: $20.00
Standard: $25.00

Description

COVID-19 convalescent plasma (CCP) from individuals recently recovered from SARS-CoV-2 infection is an important therapeutic option for individuals at risk for severe complications from COVID-19. Ensuring donor safety is of paramount importance for collection of CCP. Common donor adverse events (DAEs) generally involve complications such as vasovagal reactions, local arm pain or hematomas, as well as reactions related to apheresis collections. Other unique aspects related to donor health in individuals recovered from COVID-19 must also be considered, including donors who have received COVID-19 Convalescent Plasma (CCP) or monoclonal antibody therapy, as well as SARS-CoV-2 vaccination post-recovery. The AABB Donor Hemovigilance Working Group will share the results from their multi-institutional study analyzing key safety metrics related to the collection of CCP. Join this session to learn about new insights on donor hemovigilance gleaned from recent efforts collecting CCP.


To view Spanish or English subtitles, click the "CC" box in the video player.
Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.


Learning Objectives:
  • Identify challenges encountered by blood centers with the collection of CCP donors related to the impact of unique eligibility requirements
  • List examples of common blood center protocols to improve donation safety during the COVID-19 pandemic
  • Recognize differences in risks factors for donor adverse events (DAEs) in CCP donors compared to conventional plasma donors identified in a large multicenter study
  • Define acceptance criteria for collection of COVID-19 Convalescent Plasma (CCP) and variations between organizations screening for suitable donors

Speaker(s):

  • Dr. Jed B. Gorlin, MD, MBA, Medical Director and Vice President, Quality and Regulatory Affairs, Co-Director, Transfusion Medicine, Associate Clinical Professor, Laboratory Medicine and Pediatrics, Innovative Blood Resources
  • Dr. Mary Townsend, MD, Medical Director, Vitalant

Moderator(s):

Disclosures

  • Nancy Van Buren, MD : Nothing to Disclose
  • Jed Gorlin, MD, MBA : Nothing to Disclose
  • Mary Townsend, MD : Consultant: Cerus: Medical Advisory Board, non-paid: Terumo

Credits Available


AM21-56: COVID-19 Convalescent Plasma: Impact on Donation Safety and Eligibility Evaluation

You must be logged in and own this session in order to post comments.